Overview

• The deal includes a £9 million deferred payment due in 15 months and transfers the UK and European SlimFast business from Glanbia.
• SlimFast’s UK and European assets generated £25.5 million in unaudited 2024 revenue and £9.7 million in adjusted gross profit.
• Supreme plans to move all powder manufacturing in-house and use its distribution network to expand sales of the brand.
• The company frames SlimFast as a fit for rising GLP-1 weight-loss drug use, with the market estimated at about $50 billion in 2024 and forecast to double by decade-end.
• Analysts described the acquisition as earnings-enhancing and a diversification away from vaping, and Supreme’s shares rose more than 6% after the announcement.